Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA (CATARA)

This study has been withdrawn prior to enrollment.
(decision of sponsor to withdraw before initiation; 0 patients enrolled)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Mark Genovese, Stanford University
ClinicalTrials.gov Identifier:
NCT01204138
First received: September 10, 2010
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: December 2011
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)